Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy.
Chen YJ, Li GN, Li XJ, Wei LX, Fu MJ, Cheng ZL, Yang Z, Zhu GQ, Wang XD, Zhang C, Zhang JY, Sun YP, Saiyin H, Zhang J, Liu WR, Zhu WW, Guan KL, Xiong Y, Yang Y, Ye D, Chen LL. Chen YJ, et al. Among authors: liu wr. Sci Adv. 2023 Apr 28;9(17):eadg0654. doi: 10.1126/sciadv.adg0654. Epub 2023 Apr 28. Sci Adv. 2023. PMID: 37115931 Free PMC article.
SIRT5 inhibits peroxisomal ACOX1 to prevent oxidative damage and is downregulated in liver cancer.
Chen XF, Tian MX, Sun RQ, Zhang ML, Zhou LS, Jin L, Chen LL, Zhou WJ, Duan KL, Chen YJ, Gao C, Cheng ZL, Wang F, Zhang JY, Sun YP, Yu HX, Zhao YZ, Yang Y, Liu WR, Shi YH, Xiong Y, Guan KL, Ye D. Chen XF, et al. Among authors: liu wr. EMBO Rep. 2018 May;19(5):e45124. doi: 10.15252/embr.201745124. Epub 2018 Feb 28. EMBO Rep. 2018. PMID: 29491006 Free PMC article.
Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack.
Fang Y, Liu W, Tang Z, Ji X, Zhou Y, Song S, Tian M, Tao C, Huang R, Zhu G, Jiang X, Gao J, Qu W, Wang H, Zhou P, Wu X, Jin L, Sun H, Ding Z, Peng Y, Zhao S, Zhou J, Fan J, Xu W, Shi Y. Fang Y, et al. Hepatology. 2023 Jan 1;77(1):109-123. doi: 10.1002/hep.32348. Epub 2022 Feb 7. Hepatology. 2023. PMID: 35043976
Targeting HNRNPM Inhibits Cancer Stemness and Enhances Antitumor Immunity in Wnt-activated Hepatocellular Carcinoma.
Zhu GQ, Wang Y, Wang B, Liu WR, Dong SS, Chen EB, Cai JL, Wan JL, Du JX, Song LN, Chen SP, Yu L, Zhou ZJ, Wang Z, Zhou J, Shi YH, Fan J, Dai Z. Zhu GQ, et al. Among authors: liu wr. Cell Mol Gastroenterol Hepatol. 2022;13(5):1413-1447. doi: 10.1016/j.jcmgh.2022.02.006. Epub 2022 Feb 12. Cell Mol Gastroenterol Hepatol. 2022. PMID: 35158098 Free PMC article.
Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis.
Sun R, Zhang Z, Bao R, Guo X, Gu Y, Yang W, Wei J, Chen X, Tong L, Meng J, Zhong C, Zhang C, Zhang J, Sun Y, Ling C, Tong X, Yu FX, Yu H, Qu W, Zhao B, Guo W, Qian M, Saiyin H, Liu Y, Liu RH, Xie C, Liu W, Xiong Y, Guan KL, Shi Y, Wang P, Ye D. Sun R, et al. J Hepatol. 2022 Aug;77(2):453-466. doi: 10.1016/j.jhep.2022.02.030. Epub 2022 Mar 12. J Hepatol. 2022. PMID: 35292350
Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study.
Qu WF, Ding ZB, Qu XD, Tang Z, Zhu GQ, Fu XT, Zhang ZH, Zhang X, Huang A, Tang M, Tian MX, Jiang XF, Huang R, Tao CY, Fang Y, Gao J, Wu XL, Zhou J, Fan J, Liu WR, Shi YH. Qu WF, et al. Among authors: liu wr. BJS Open. 2022 Sep 2;6(5):zrac114. doi: 10.1093/bjsopen/zrac114. BJS Open. 2022. PMID: 36125345 Free PMC article.
317 results